跳至主要内容
临床试验/NCT02163174
NCT02163174已完成3 期

Pentoxifylline Therapy of Late-onset Sepsis in Preterm Infants: A Randomized Controlled Trial.

Abd Elazeez Attala Shabaan1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2011年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
120
试验地点
1
主要终点
Neonatal mortality

研究概览

简要总结

  • Hypothesis: The investigators hypothesized that Pentoxifylline has potent anti-inflammatory effect which can augment the antimicrobial effect of antibiotics in treatment of Late onset sepsis (LOS) in preterm infants thus decreasing neonatal mortality and morbidity.
  • The purpose of this study: to assess the efficacy and safety of Pentoxifylline as an adjunct to antibiotic therapy on mortality and morbidity of preterm infants with LOS.

详细描述

  • Role of pentoxifylline, a phosphodiesterase inhibitor, in reducing mortality associated with neonatal sepsis is not well studied.
  • Hypothesis: we hypothesized that Pentoxifylline has potent anti-inflammatory effect which can augment the antimicrobial effect of antibiotics in treatment of Late onset sepsis (LOS) in preterm infants thus decreasing neonatal mortality and morbidity.
  • Purpose of the study: to assess the efficacy and safety of Pentoxifylline as an adjunct to antibiotic therapy on mortality and morbidity of preterm infants with LOS.
  • Design: A prospective, randomized, double-blind clinical trial.
  • Setting: Neonatal Intensive Care Unit, Mansoura University Children's Hospital.
  • Patients: 120 preterm infants with suspected or confirmed LOS.
  • Intervention: Enrolled infants were randomly assigned to receive intravenous Pentoxifylline (5 mg/kg/hr for 6 hours on 6 successive days) or placebo in addition to antibiotics.
  • Primary outcome: Death before hospital discharge.
  • Secondary outcomes: Length of hospital stay, duration of respiratory support, duration of antibiotics use, chronic lung disease, necrotizing enterocolitis, intraventricular hemorrhage, periventricular leukomalacia, retinopathy of prematurity, Serum levels of Tumor necrosis factor, C-Reactive protein levels, and adverse effects of Pentoxifylline.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
5 Days 至 7 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • Appropriate for gestational age preterm infants with suspected or confirmed late onset sepsis

排除标准

  • Preterm infants with major congenital malformations
  • Preterm infants with chromosomal anomalies
  • Preterm infants with inborn-errors of metabolism
  • Preterm infants with congenital infection

研究组 & 干预措施

Pentoxyfilline arm

Active Comparator

Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics.

干预措施: Pentoxifylline (PTX) (Drug)

Placebo arm

Placebo Comparator

Intravenous saline as a Placebo 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics.

干预措施: Placebo (Drug)

结局指标

主要结局

Neonatal mortality

时间窗: Expected 10 weeks postnatal age

Mortality before discharge from neonatal intensive care unit

次要结局

  • Length of hospital stay(Expected average of 8 weeks post natal age)
  • Duration of respiratory support(Expected 4 to 6 weeks postnatal age)
  • Duration of antibiotics use(Expected 3 to 5 weeks postnatal age)
  • Chronic lung disease(By 36 weeks corrected gestational age)
  • Necrotising enterocolitis(Expected 6 weeks)
  • Intraventricular haemorrhage(Expected 2 weeks)
  • Periventricular leukomalacia(Expected 8 weeks)
  • Serum levels of Tumor necrosis factor-α, C-Reactive protein(6 days after intervention)
  • Retinopathy of prematurity(Expected 8 weeks)
  • Adverse effects of Pentoxifylline(Up to 10 days after intervention)

研究者

发起方
Abd Elazeez Attala Shabaan
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Abd Elazeez Attala Shabaan

Associate Professor of Pediatrics, Mansoura faculty of Medicine

Mansoura University

研究点 (1)

Loading locations...

相似试验